Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin for lowering uric acid in type 2 diabetes mellitus with hyperuricemia
ChiCTR2400083831Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of henagliflozin in type 2 diabetes mellitus (T2DM) and hyperuricemia (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Change in serum uric acid from baseline. Started Apr 2024; status: recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hyperuricemia
Beyond the preview
Go deeper on ChiCTR2400083831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083831.